for the BSR Biologics Register Management committee
Background
Anti-TNF-therapy has been shown to be effective in the treatment of rheumatoid arthritis (RA) [1] [2] [3] , juvenile idiopathic arthritis (JIA) [4] , psoriatic arthritis (PsA) [5] [6] [7] and ankylosing spondylitis (AS) [8] [9] [10] , both in terms of randomized controlled trials and patients' experience [11, 12] . Etanercept and infliximab were approved for use in JIA (etanercept only) and RA by the National Institute for Health and Clinical Excellence (NICE) [13, 14] for England and Wales, whose guidance is also followed in Northern Ireland [15] , and by similar mechanisms in Scotland [16, 17] , meaning that they should be available for all patients meeting the specified criteria in the UK. Similarly, the Scottish Medicines Consortium has approved etanercept and adalimumab for use in RA [14] in Scotland. The British Society for Rheumatology's Guidelines Working Party [18] has issued guidance for use of these agents in PsA [19] and AS [20] , but these carry no requirement for local purchasers to fund such usage. Guidance also exists for screening patients for risk of tuberculosis before treatment is started [21, 22] .
One of the criteria for use of anti-tumour necrosis factor (anti-TNF) therapy for RA specified by NICE was that patients should be entered into a national registry, and so the British Society for Rheumatology established a Biologics Register (BSRBR), run by the arc Epidemiology Research Unit in Manchester [23] [24] [25] , and the British Society for Paediatric and Adolescent Rheumatology has established a similar registry for children with JIA [26] . These registries are designed to investigate toxicity (including adverse events and particularly malignancy) and efficacy of these drugs in UK clinical practice, compared with control cohorts, but can also highlight variations in frequency of drug use. Although the BSRBR was designed and funded to record data about patients with RA treated with biological agents, in reality a number of patients treated for other conditions and with other agents (e.g. rituximab) have been included. The BSRBR is producing important results but creates a workload for already busy clinicians.
The BSRBR management committee wished to establish clinicians' views and experience of use of anti-TNF therapy and the register, as well as understanding reasons for apparent regional variations in prescribing rates of these drugs.
Methods
A questionnaire was sent to all consultant rheumatologist members of the BSR in January 2006. The questionnaire was anonymous and gave the option of being completed on behalf of a unit or department, or individually. A second copy of the questionnaire was e-mailed to all members 4 weeks later. The questionnaire comprised questions about numbers of patients treated, their diagnoses, any limitations on access to therapies, use of and views on the current registry and the need for any future registries, and current practice relating to screening for tuberculosis and use of BSR guidance. Returned questionnaires were analysed using EPI INFO version 6.
Results
A total of 509 questionnaires were sent out. Of that, 136 responses were received on behalf of 252 consultants. A median of 1.9 consultants was covered per return, with a range of 1-7. Limitations in prescribing anti-TNF-therapy in RA Fifty-six (42%) of the responses, representing 115 (46%) consultants, indicated that they had some form of limitation in their prescribing of anti-TNF-agents for RA according to NICE guidance. These limitations were mainly in the form of capped funding or numbers of patients (40; 70%), staffing (12; 21%) or lack of other facilities (4; 9%). Free text responses included fixed numbers of patients to be treated per month, fixed financial caps, the presence of different limits for different Primary Care Trusts (funding bodies) and recent impositions of bans on treating any more patients until the next financial year.
Forty-eight (36%) of the responses indicated that the department had a waiting list of patients. The median waiting time for all patients was 4 weeks, with a maximum wait described of 156 weeks (interquartile range 2-12 weeks).
Additionally, 33 (25%) respondents described other restrictions in use of anti-TNF-therapy in RA, including 14 (45%) who were not able to switch agents for patients where treatment was stopped because of toxicity and/or inefficacy, and 11 (36%) who were not able to prescribe adalimumab, which is not mentioned in the NICE guidance as it was not licensed at the time they were issued.
Prescribing of anti-TNF-therapy for AS and PsA
Ninety (67%) of the respondents are able to prescribe anti-TNFtherapy for AS and/or PsA in at least some circumstances, meaning that 44 (33%) have no access to these drugs for these conditions at all. Some respondents could be from Scotland where anti-TNF-therapies for PsA [27] and AS [28] have been approved by the Scottish Medicines Consortium, but as the questionnaire was anonymous we are unable to identify them separately. Seventy-six consultants are completely unable to prescribe anti-TNF therapy for AS, PsA or both, despite the drugs being licensed in the UK. The ability to prescribe according to BSR guidance was limited to 61/252 (25%) consultants for AS and 76/252 (30%) consultants for PsA (Fig. 1) . Again, in the free text responses some indicated that they could only prescribe where a patient who moved into the area had already received such treatment, named cases for compassionate reasons only could be treated, restrictions were increasing or that the drugs would not be available to them until NICE mandates their use.
Screening for tuberculosis
Over 99% of consultants (all except one) routinely check a chest X-ray to look for evidence of previous pulmonary tuberculosis. One hundred and twenty-five consultants (93%) take a specific history of tuberculosis infection or exposure, 60 (44%) examine for a BCG scar, 39 (29%) use a Heaf or Mantoux test and 12 (9%) use a serological immunological test.
Experience of the registry
Sixteen respondents (14%) described difficulty in submitting data to the BSRBR, most commonly through lack of time or difficulty in obtaining case notes at appropriate times. Fifty-one (39%) found the workload involved in submitting information to the BSRBR manageable, whereas 65 (49%) found it difficult, 12 (9%) found it very onerous and 3 found it impossible. Eighty-four per cent had assistance from a nurse at least partly funded by the National Health Service in completing the documentation.
Forty-four (38%) of the respondents had requested information from the registry. Twenty-five made free text comments representing a strongly positive experience, particularly referring to speed and helpfulness of the response, 5 had found the response fair or satisfactory and 5 reported a poor or unhelpful response, largely a lack of reply. Forty-two respondents had attended the BSRBR Open Meeting at the 2005 BSR Annual Meeting, where data from the BSRBR were presented, of whom 41 had found it useful or partly useful. One hundred and sixteen (87%) had received the annual report of their own data from BSRBR and 41 (35%) had requested a combined report for their department. Usefulness was rated at a median of 7/10 (interquartile range 5-8). The report had been used for internal audit purposes, appraisal, comparing oneself with others and in applications for funding. One unit discovered that patients had not been registered by the nurse as had been thought.
For the future, the majority of respondents felt that similar registries for AS, PsA and rituximab would be desirable (53, 56 and 36%) or essential (41, 38 and 60%, respectively) to answer questions about toxicity, particularly rare side effects, withdrawal rates and efficacy of these therapies.
Use of BSR guidelines concerning anti-TNF-therapy
Levels of awareness and use of BSR guidance about the use of anti-TNF-therapy in RA, AS and PsA were high. Only 1% were unaware of the guidance concerning RA (13% for AS and 16% for PsA), and the guidelines were used in routine practice by the majority (99% for RA, 73% AS and 71% PsA).
Conclusions
This survey describes UK consultant rheumatologists' use of and access to anti-TNF-therapy and their experience of and views about the BSRBR. The most striking findings are of the restrictions in access to anti-TNF-agents, even in areas where their use has been mandated, such as for RA in England and Wales according to NICE guidance [14] . Over 40% of consultants are limited in their ability to prescribe anti-TNF-for patients with RA who meet NICE criteria for treatment (although a minority of these consultants may practise in regions not covered by NICE). This limitation is most commonly in the form of UK anti-TNF therapy use and the BSR Biologics Registera financial or numerical cap implemented by funding organizations, which is in direct contravention of government policy [29] . Long waiting times for patients to receive these drugs once a decision to prescribe has been made are not uncommon, which will add further to their deterioration and compromise their likely outcome. For indications for these therapies that have not yet received a decision from NICE; access to treatment is also limited. Only 67% of consultants have any access to anti-TNF-therapy for their patients with PsA or AS, whilst ability to prescribe according to BSR guidance is limited to 25% for AS and 30% for PsA. Consultants are aware of and use the BSR guidance for use of anti-TNF therapy in these conditions [14, 19, 20] , and there is evidence elsewhere that their use has increased the uniformity of assessment of patients' suitability for treatment, amongst consultants [15] . The fact that different funding organizations set different restrictions has led to variation of access for equally affected patients to effective treatment, depending on where they live. As the survey was anonymous the disparity in provision cannot be mapped from our data.
The guidelines from the British Thoracic Society concerning assessment of risk of tuberculosis infection in patients being considered for anti-TNF-therapy [21] are generally followed. Whilst use of a chest X-ray is almost universal, a small number of consultants indicated that they do not specifically take a history of previous tuberculosis infection or exposure, and the role of the tuberculin skin test remains difficult to define [22] .
Consultant contributors generally view the BSRBR positively, although most regard the workload as difficult, and similar registries for other conditions and new drugs are viewed as important. Most have had little difficulty in submitting data, have met with a good response from the Register when making enquiries and have found the individual consultant annual report to be useful.
The BSRBR has the primary purpose of describing toxicity and efficacy of anti-TNF agents in their real-world use in RA, but this work has shown that it also has a role in monitoring provision of these agents and in clinical governance for rheumatologists.
